Incidence and management of malignant digestive endocrine tumours in a well defined French population

被引:117
作者
Lepage, C [1 ]
Bouvier, AM [1 ]
Phelip, JM [1 ]
Hatem, C [1 ]
Vernet, C [1 ]
Faivre, J [1 ]
机构
[1] Fac Med, INSERM, Registre Bourguignon Canc Digest, F-21079 Dijon, France
关键词
D O I
10.1136/gut.2003.026401
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and aims: Little is known about the epidemiology of malignant digestive endocrine tumours. The aim of this study was to report on their incidence and management in a well defined population. Methods: Data were obtained from the population based Digestive Cancer Registry of Burgundy ( France) over a 24 year period. Incidence rates were calculated by sex, age groups, and period of diagnosis. Treatment and stage at diagnosis were also investigated. Prognosis was determined using crude and relative survival rates. A multivariate relative survival analysis was performed. Results: Between 1976 and 1999, 229 cases were recorded. Age standardised incidence rates were 0.76/100 000 for men and 0.50/100 000 for women. They increased over time in both sexes. The resectability rate was 74.1%. Among recorded cases, 26.6% did not extend beyond the organ, 20% had lymph node metastases, and 53.3% had visceral metastases or were unresectable. There was no improvement in the resection rate or in the stage at diagnosis over the study period. The overall relative survival rate was 66.9% at one year, 50.4% at five years, and 40.6% at 10 years. Stage at diagnosis, age at diagnosis, and subsite were independent significant prognostic factors. Conclusions: Although their incidence is increasing, malignant digestive endocrine tumours remain a rare cancer, representing 1% of digestive cancers. Stage at diagnosis and prognosis at a population level are worse than those reported in hospital series. In the short term, new therapeutic possibilities represent the best way to improve their prognosis.
引用
收藏
页码:549 / 553
页数:5
相关论文
共 27 条
  • [1] BALLANTYNE GH, 1992, CANCER, V69, P2400, DOI 10.1002/1097-0142(19920515)69:10<2400::AID-CNCR2820691003>3.0.CO
  • [2] 2-Z
  • [3] BERGE T, 1976, ACTA PATH MICRO IM A, V84, P322
  • [4] PANCREATIC-ISLET CELL-CARCINOMA .2. RESULTS OF THERAPY WITH STREPTOZOTOCIN IN 52 PATIENTS
    BRODER, LE
    CARTER, SK
    [J]. ANNALS OF INTERNAL MEDICINE, 1973, 79 (01) : 108 - 118
  • [5] Burke AP, 1997, CANCER-AM CANCER SOC, V79, P1086, DOI 10.1002/(SICI)1097-0142(19970315)79:6<1086::AID-CNCR5>3.3.CO
  • [6] 2-8
  • [7] Digestive neuroendocrine tumours: diagnosis and treatment in Italy. A survey by the Oncology Study Section of the Italian Society of Gastroenterology (SIGE)
    Corleto, VD
    Panzuto, F
    Falconi, M
    Cannizzaro, R
    Angeletti, S
    Moretti, A
    Delle Fave, G
    Farinati, F
    [J]. DIGESTIVE AND LIVER DISEASE, 2001, 33 (03) : 217 - 221
  • [8] Evans EB., 2000, CLIN ENDOCRINOL, V53, P259
  • [9] Colon cancer in France: evidence for improvement in management and survival
    Faivre-Finn, C
    Bouvier-Benhamiche, AM
    Phelip, JM
    Manfredi, S
    Dancourt, V
    Faivre, J
    [J]. GUT, 2002, 51 (01) : 60 - 64
  • [10] HEDELIN G, 1995, RELSURV 1 0 PROGRAM